Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Emerging treatments for wet age-related macular degeneration.

Smith AG, Kaiser PK.

Expert Opin Emerg Drugs. 2014 Mar;19(1):157-64. doi: 10.1517/14728214.2014.884559. Review.

PMID:
24555421
2.

Current advances in the treatment of neovascular age-related macular degeneration.

Villegas VM, Aranguren LA, Kovach JL, Schwartz SG, Flynn HW Jr.

Expert Opin Drug Deliv. 2017 Feb;14(2):273-282. doi: 10.1080/17425247.2016.1213240. Epub 2016 Aug 2. Review.

PMID:
27434329
3.

Neovascular age-related macular degeneration: potential therapies.

Chappelow AV, Kaiser PK.

Drugs. 2008;68(8):1029-36. Review.

PMID:
18484796
4.

Anti-VEGF agents for age-related macular degeneration.

Ozkiris A.

Expert Opin Ther Pat. 2010 Jan;20(1):103-18. doi: 10.1517/13543770902762885. Review.

PMID:
20021287
5.

Drugs in Phase II clinical trials for the treatment of age-related macular degeneration.

Tolentino MJ, Dennrick A, John E, Tolentino MS.

Expert Opin Investig Drugs. 2015 Feb;24(2):183-99. doi: 10.1517/13543784.2015.961601. Epub 2014 Sep 22. Review.

PMID:
25243494
6.

Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration.

Ohr M, Kaiser PK.

Expert Opin Pharmacother. 2012 Mar;13(4):585-91. doi: 10.1517/14656566.2012.658368. Epub 2012 Feb 3. Review.

PMID:
22300011
8.

Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration.

Aisenbrey S, Ziemssen F, Völker M, Gelisken F, Szurman P, Jaissle G, Grisanti S, Bartz-Schmidt KU.

Graefes Arch Clin Exp Ophthalmol. 2007 Jul;245(7):941-8. Epub 2006 Dec 21.

PMID:
17186262
9.

Emerging therapies for the treatment of wet age-related macular degeneration--VEGF Trap-Eye.

Rejdak R, Szkaradek M, Grieb P, Jünemann AG.

Klin Oczna. 2011;113(10-12):376-8. Review.

PMID:
22384659
10.

[Subretinal hemorrhage after intravitreal injection of anti-VEGF for age-related macular degeneration: a retrospective study].

Baeteman C, Hoffart L, Galland F, Ridings B, Conrath J.

J Fr Ophtalmol. 2009 May;32(5):309-13. doi: 10.1016/j.jfo.2009.04.001. Epub 2009 May 17. French.

11.

Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD).

Rasmussen H, Chu KW, Campochiaro P, Gehlbach PL, Haller JA, Handa JT, Nguyen QD, Sung JU.

Hum Gene Ther. 2001 Nov 1;12(16):2029-32.

PMID:
11727737
13.

New treatments for age-related macular degeneration.

Mittra RA, Ramsay RC.

Minn Med. 2009 Jun;92(6):41-4.

PMID:
19653472
14.

[The results of wet AMD treatment by intravitreal injections--preliminary report].

Okruszko A, Borucka AI, Ulińska M, Szaflik J.

Klin Oczna. 2007;109(10-12):389-93. Polish.

PMID:
18488380
15.

An update on the pharmacotherapy of neovascular age-related macular degeneration.

Freund KB, Mrejen S, Gallego-Pinazo R.

Expert Opin Pharmacother. 2013 Jun;14(8):1017-28. doi: 10.1517/14656566.2013.787410. Epub 2013 Apr 8. Review.

PMID:
23560774
16.

A safety evaluation of ranibizumab in the treatment of age-related macular degeneration.

Gibson JM, Gibson SJ.

Expert Opin Drug Saf. 2014 Sep;13(9):1259-70. doi: 10.1517/14740338.2014.939951. Epub 2014 Aug 5. Review.

PMID:
25091039
17.

What is new in the management of wet age-related macular degeneration?

Sivaprasad S, Hykin P.

Br Med Bull. 2013;105:201-11. doi: 10.1093/bmb/ldt004. Epub 2013 Feb 7.

PMID:
23393060
18.
19.

Anti-angiogenic therapy of exudative age-related macular degeneration: current progress and emerging concepts.

Noël A, Jost M, Lambert V, Lecomte J, Rakic JM.

Trends Mol Med. 2007 Aug;13(8):345-52. Epub 2007 Jul 17. Review.

20.

Supplemental Content

Support Center